Search

Your search keyword '"Ian Taylor"' showing total 1,099 results

Search Constraints

Start Over You searched for: Author "Ian Taylor" Remove constraint Author: "Ian Taylor"
1,099 results on '"Ian Taylor"'

Search Results

1. Rapid 3D imaging at cellular resolution for digital cytopathology with a multi-camera array scanner (MCAS)

2. Responsible government and responsible business: the challenge of harnessing CSR in a new epoch

3. Incorporating patient and public involvement (PPI) at the design stage of an early career physiotherapy researcher's funding application: A co-produced reflective case report

4. Key parameters linking cyber-physical trust anchors with embedded internet of things systems

5. Single-cell transcriptomic profile of human pulmonary artery endothelial cells in health and pulmonary arterial hypertension

6. Sixty Years Later: Africa’s Stalled Decolonization

7. Current knowledge, status, and future for plant and fungal diversity in Great Britain and the UK Overseas Territories

8. A Marriage of Convenience on the Rocks? Revisiting the Sino–Angolan Relationship

9. Connecting supplier and DoD blockchains for transparent part tracking

10. Verifiable Badging System for scientific data reproducibility

11. Development of a Mobile, Self-Sovereign Identity Approach for Facility Birth Registration in Kenya

12. Structural characterisation of the Chaetomium thermophilum Chl1 helicase.

14. Why We Need a World Development Organisation

16. The Limits of the EU as a Peace and Security Actor in the Democratic Republic of the Congo Grenzen der EU bei der Schaffung von Frieden und Sicherheit in der Demokratischen Republik Kongo

18. The Reliability and Validity of a Self-Report Measure of Cognitive Abilities in Older Adults: More Personality than Cognitive Function

19. South Africa and the Emerging Powers

21. Review: Devan Pillay, Gilbert M. Khadiagala, Prishani Naidoo and Roger Southall (eds), New South African Review 4: A Fragile Democracy – Twenty Years On (2014)

31. Government science ambitions require greater funding and wider public understanding

33. Supplementary Table 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

35. Supplementary Figure 4 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

37. Supplementary Figure 6 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

38. Supplementary Table 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

39. Data from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

40. Supplementary Figure 7 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

41. Supplementary Figure 3 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

42. Supplementary Figure 5 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

43. Supplementary Figure 2 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

44. Supplementary Figure 1 from Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib

45. Data from Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors

48. Tertiary Lymphoid Structures Sustain Cutaneous B cell Activity in Hidradenitis Suppurativa

Catalog

Books, media, physical & digital resources